Trial NCT00401401

View at ClinicalTrials.gov 
Org. Study IDs: Hx-EGFr-203

Last trial update was posted on 2011-12-23

MeSH Interventions

Zalutumumab

MeSH Conditions

Carcinoma, Squamous Cell Head and Neck Neoplasms Neoplasms, Squamous Cell

Other Conditions

Head and Neck Cancer Squamous Cell Cancer

Stopping Reasons

MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.

Limitations And Caveats

All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years. The planned parallell group of the study was cancelled.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID